Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/1999
10/14/1999WO1999051641A1 G-protein fusion receptors and chimeric gabab receptors
10/14/1999WO1999051640A1 Human oxidized ldl receptor
10/14/1999WO1999051639A1 An integrin heterodimer and a subunit thereof
10/14/1999WO1999051638A1 DUAL Avb3 AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS
10/14/1999WO1999051637A1 Mammalian selenoprotein differentially expressed in tumor cells
10/14/1999WO1999051635A1 Transcription factors and their use
10/14/1999WO1999051634A1 Human gap junction protein beta-3
10/14/1999WO1999051633A1 Proteins having immunomodulatory activity and remedies for immunological diseases
10/14/1999WO1999051627A1 Method for searching physiologically active substances, process for producing theses substances and drugs found by the searching method
10/14/1999WO1999051626A2 Template associated npy y2-receptor agonists
10/14/1999WO1999051624A1 Reagents and methods for inhibiting furin protease activity
10/14/1999WO1999051622A1 Avian il-15 nucleotides and polypeptides, and methods of immunizing poultry using avian il-15
10/14/1999WO1999051596A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051595A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051275A2 Mesenchymal stem cells as immunosuppressants
10/14/1999WO1999051272A1 Injectable igf-formulations containing succinate as buffering agent
10/14/1999WO1999051262A2 Use of igfi for treating articular cartilage disorders
10/14/1999WO1999051261A1 Use of urocortin and like polypeptides in therapy
10/14/1999WO1999051260A2 Treatment of cardiac hypertrophy
10/14/1999WO1999051259A2 Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
10/14/1999WO1999051258A1 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE
10/14/1999WO1999051257A1 Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient
10/14/1999WO1999051256A2 Use of l-glu-l-trp in the treatment of hiv infection
10/14/1999WO1999051254A1 Short peptides for treatment of neurological degenerative diseases
10/14/1999WO1999051253A2 Immune response modulation
10/14/1999WO1999051248A1 New combined preparation for the treatment of neoplasic diseases or of infectious diseases
10/14/1999WO1999051247A1 Use of human mesenchymal stem cells to induce t-cell apoptosis
10/14/1999WO1999051243A1 THE USE OF ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY
10/14/1999WO1999051233A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051232A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051231A1 Antagonists of gonadotropin releasing hormone
10/14/1999WO1999051226A1 Use of aminothiazole derivatives for preparing medicines for treating diseases causing demyelinization
10/14/1999WO1999051217A1 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof
10/14/1999WO1999051215A2 Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
10/14/1999WO1999051205A1 Aerosol composition
10/14/1999WO1999051188A2 A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
10/14/1999WO1999051187A2 A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
10/14/1999WO1999051185A2 Human galactosyl transferases
10/14/1999WO1999044628A8 Conjugates useful in the treatment of prostate cancer
10/14/1999WO1999043809A3 Protease-activated receptor 4 and uses thereof
10/14/1999WO1999043705A8 N-terminally truncated glp-1 derivatives
10/14/1999WO1999043701A3 Peptides for inhibition of apoptosis and pharmaceutical compositions containing them
10/14/1999WO1999043361A8 Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
10/14/1999WO1999042579A3 Caf1-related protein
10/14/1999WO1999042076A3 Compounds and methods for immunotherapy and diagnosis of tuberculosis
10/14/1999WO1999042075A3 Antibodies against human cd40
10/14/1999WO1999040188A3 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations
10/14/1999WO1999039729A3 Use of heregulin as an epithelial cell growth factor
10/14/1999WO1999039724A9 Treatment of bony defects with osteoblast precursor cells
10/14/1999WO1999039702A3 Method for regulating size and growth of vascularized normal tissue
10/14/1999WO1999038958A9 SUBSTRATE ANALOGS FOR MurG, METHODS OF MAKING SAME AND ASSAYS USING SAME
10/14/1999WO1999037803A3 INHIBITION OF DNA MODULATION CAUSED BY MUTATED p53
10/14/1999WO1999037678A3 Antimicrobial peptides
10/14/1999WO1999037660A9 Meth1 and meth2 polynucleotides and polypeptides
10/14/1999WO1999036544A3 Neisseria meningitidis antigens
10/14/1999WO1999036094A9 Composition and method for treating metastatic tumors or cancer induced by cells expressing sv40 tumor antigen
10/14/1999WO1999033999A9 Mitogen-activated protein kinase kinase 7 (mkk7)
10/14/1999WO1999032080A3 Device for targeted immobilization of the thrombogenic inhibitor hirudine on polymer surfaces
10/14/1999WO1999031225A3 Human phosphatases
10/14/1999WO1999028343A9 Hydrophobically-modified protein compositions and methods
10/14/1999WO1999026660A3 Conjugates of cytokines and drugs or genes for treating proliferating cells
10/14/1999WO1999022773A3 Sequences for targeting metastatic cells
10/14/1999WO1999021589A3 Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
10/14/1999WO1999019488A8 Novel human egf receptors and use thereof
10/14/1999WO1999010486A3 Mdm2-specific antisense oligonucleotides
10/14/1999DE19816035A1 Treatment of hemochromatosis with erythropoietin
10/14/1999DE19815812A1 New camptothecin derivatives useful as cytostatic agents for treating cancer
10/14/1999DE19815331A1 Transkriptionsfaktoren und deren Verwendung Transcription factors and their use
10/14/1999DE19815060A1 Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie Pharmaceutical preparations for the therapy of side effects during and / or after a GnRHa therapy
10/14/1999DE19807426A1 Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs A method for the treatment of diseases or disorders of the inner ear
10/14/1999CA2740948A1 Antibody variants and fragments thereof
10/14/1999CA2327814A1 Reagents and methods for inhibiting furin protease activity
10/14/1999CA2327811A1 Short peptides for treatment of neurological degenerative diseases
10/14/1999CA2326760A1 Use of l-glu-l-trp in the treatment of hiv infection
10/14/1999CA2326739A1 Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient
10/14/1999CA2326598A1 Fusion proteins of mycobacterium tuberculosis antigens and their uses
10/14/1999CA2326388A1 A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
10/14/1999CA2326185A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326184A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326146A1 Template associated npy y2-receptor agonists
10/14/1999CA2326143A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326140A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2326066A1 A interleukin-1 receptor antagonist and uses thereof
10/14/1999CA2325995A1 Antagonists of gonadotropin releasing hormone
10/14/1999CA2325562A1 Lyst protein complexes and lyst interacting proteins
10/14/1999CA2325354A1 Highly active forms of interferon regulatory factor proteins
10/14/1999CA2325342A1 Dual avb3 and metastasis-associated receptor ligands
10/14/1999CA2325341A1 Mutagenized il13-based chimeric molecules
10/14/1999CA2325339A1 Dadd, death activator death domain protein
10/14/1999CA2325334A1 G-protein fusion receptors and chimeric gabab receptors
10/14/1999CA2325007A1 Human galactosyl transferases
10/14/1999CA2324984A1 Secreted proteins and polynucleotides encoding them
10/14/1999CA2324976A1 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof
10/14/1999CA2324868A1 Human oxidized ldl receptor
10/14/1999CA2324656A1 Protein variant of the net1 locus
10/14/1999CA2324510A1 Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
10/14/1999CA2324381A1 An integrin heterodimer and a subunit thereof
10/14/1999CA2324378A1 Glaucoma therapeutics and diagnostics
10/14/1999CA2268640A1 Composition for preventing or treating ischemic disease
10/13/1999EP0949332A2 HSSCRG1 polypeptides
1 ... 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 ... 3163